Parabilis Medicines
Parabilis Medicines Raises $305M Series F | Precision Medicine Platform
Parabilis Medicines Closes $305M Series F
Parabilis Medicines, a biotechnology company developing precision medicines, has raised $305 million in Series F funding.
The round was co-led by RA Capital Management, Fidelity, and Janus Henderson Investors.
Key Highlights
- Late-stage biotech funding
- Focus on precision medicine
- Strong institutional backing
Company Overview
Parabilis Medicines is advancing a pipeline of precision medicines targeting genetic drivers of disease, with multiple programs in clinical development.
Company Info
Investors (3)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started